CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Breast cancer patients whose tumors have spread to other parts of their bodies live from scan to scan. Is their treatment ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

AstraZeneca's new breast cancer pill, Camizestrant, shows promising results. The drug delayed cancer progression by over six ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Pomerantz LLP is investigating claims on behalf of investors of  Tempus AI, Inc. ("Tempus" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...